Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
FDA status Neither TB-500 nor BPC-157 is FDA-approved for human therapeutic use
[133:09] Andrew Huberman Right
Thymalin is widely regarded as having a favourable safety profile, with low toxicity and minimal side effects when used within standard dosing protocols
assessed the response of a range of mild to moderate peripheral entrapment neuropathies to a combination treatment of uridine monophosphate (50 mg), folic acid (400 g) and vitamin B12 (3 g) once daily for a duration of 60 days ( n = 48)
Safety concerns included uncharacterized immunogenicity (the risk that injected peptides trigger immune reactions), inadequate impurity and endotoxin testing in available raw material, the unresolved free base versus acetate salt form distinction, and, for BPC-157 specifically, an angiogenesis mechanism that raises theoretical cancer-risk concerns for certain patient populations
